Burning Rock Biotech (NASDAQ:BNR) Issues Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) announced its earnings results on Tuesday. The company reported ($1.08) EPS for the quarter, Zacks reports. Burning Rock Biotech had a negative return on equity of 60.68% and a negative net margin of 83.50%.

Burning Rock Biotech Stock Down 12.4 %

NASDAQ BNR opened at $4.82 on Wednesday. Burning Rock Biotech has a 12-month low of $2.62 and a 12-month high of $8.99. The firm has a 50-day moving average price of $6.28 and a two-hundred day moving average price of $5.28. The company has a market capitalization of $49.38 million, a P/E ratio of -1.61 and a beta of 0.55.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.